EoS Fitness Powers into 2025, Setting New Fitness Industry Benchmarks
Q1 Was Packed with Innovations, Partnerships and Growth, Kicking Off a Game-Changing Year for the High Value. Low Price.® (HVLP) Gym
DALLAS, April 09, 2025--(BUSINESS WIRE)--EoS Fitness launched into Q1 2025 with rapid growth, a new marketing campaign, in-gym innovations and impactful partnerships, laying the groundwork for a remarkable year ahead. From unveiling Will Power — the fitness industry's first-ever brand character — to opening several new locations nationwide, EoS continues to expand and raise the bar for the fitness industry and redefine what it means to be a leader in the category.
"After a standout 2024, EoS Fitness is charging into 2025 with even bigger ambitions. We're not just evolving — we're leading the industry forward," said Rich Drengberg, chief executive officer, EoS Fitness. "Last year, we opened 21 new locations and improved every major same-store member experience, including friendliness, cleanliness, equipment condition and facility upkeep. We aim to open 28 gyms this year while continuing to invest in existing gyms and member engagement."
Meet Will Power: EoS' Newest Member
EoS made history in Q1 by introducing Will Power, a first-of-its-kind brand character in the fitness industry. Clay-sculpted in EoS' signature blue, Will's relatable persona debuted across all major marketing channels in January, setting a new benchmark for engaging members and quickly building a fan base. Celebrated for his humor, resilience and authenticity, Will Power has become a movement, capturing the attention of industry leaders and fitness enthusiasts. The campaign has already earned acclaim, winning two Gold and two Silver ADDY Awards from the American Advertising Federation Phoenix, advancing to the district level with the potential to compete nationally.
Expanding Access to Premium, Affordable Fitness Options
Continuing to expand its national footprint, EoS opened seven new gyms in key markets across four states in Q1, with six additional leases signed to fuel its long-term goal of reaching 250 locations by 2030. Blending high-end strength training and cardio equipment, innovative recovery options and signature amenities, EoS opened the following new gyms in the first quarter:
750 E. Guadalupe Road, Tempe, Arizona
3921 Bedford Canyon Road, Corona, California
335 E. Alessandro Blvd., Riverside, California
1775 N. Congress Ave., Suite B, Boynton Beach, Florida
1345 E. Osceola Parkway, Kissimmee, Florida
11230 Legacy Ave., Palm Beach Gardens, Florida
22314 FM 529 Road, Suite 100, Cypress, Texas
EoS also reinvested over $3.2 million into existing gyms in Q1 and plans to invest $14 million more through the end of the year, underscoring its continuous drive to improve and elevate member value through innovation.
Next-Level Gym Recovery: Investing in Recovery and Performance
Reinforcing its pledge to drive innovation, EoS continued to roll out its latest amenity, Refresh, in several new locations. Refresh includes a cold plunge, a hot tub and an infrared sauna in one convenient space. This unique setup allows for contrast therapy — an emerging trend in holistic fitness meeting a growing demand for gym recovery, longevity and preventative amenities aimed at restoring balance and enhancing wellness. The health benefits of contrast therapy — alternating between the cold plunge and the infrared sauna or hot tub — include improved circulation and pain management, reduced inflammation and better sleep and performance.
Strengthening Impact Through Partnerships
Celebrating the shared values of self-acceptance, inclusion and community, EoS joined forces with Zumba® for the "Say It. Believe It." campaign, inspiring people to embrace their inner confidence through movement. More than 1,670 participants came together on March 29 for Say It Saturday, a nationwide initiative with special Zumba® classes held at 34 EoS locations.
"Partnering with EoS for Say It Saturday brought our 'Say It. Believe It.' campaign to life in an unforgettable way, uniting communities through movement and confidence. It's incredible to see the impact when we come together to celebrate self-acceptance and inclusivity," said Rebecca Dorfman, vice president of consumer marketing, Zumba®.
For more information about EoS or the nearest location, visit www.eosfitness.com.
About EoS Fitness
EoS Fitness, a leader in the fitness industry with its High Value. Low Price.® (HVLP) gyms, is an inclusive and welcoming organization committed to empowering exercise practitioners of all experience levels. With more than 175 gym locations open and on the way in Arizona, Florida, Georgia, Nevada, Southern California, Texas and Utah, EoS Fitness is rapidly expanding. Providing serious fitness options, EoS Fitness offers the best equipment, high-energy workout classes, top-notch amenities, and extensive personal training options starting at just $9.99 per month. www.EoSfitness.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250409687907/en/
Contacts
Media Contact:Melissa Ruemkr@nstpr.com 208-850-5939
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
'AI-First' Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI
CAMBRIDGE, UK--(BUSINESS WIRE)--After a wave of bold 'AI-first' announcements from major tech players, many are now scaling back. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. Share As the AI gold rush slows, a new report from Speechmatics explores what's actually working — and where the real value lies. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report zeroes in on one of the fastest-evolving areas of AI: Voice AI. Built on interviews with leaders across healthcare, compliance, media, public services, and research, it reveals a clear shift from flashy demos to embedded, operational AI — where tools assist humans, deliver measurable ROI, and quietly power core infrastructure. Report highlights include: Assistive over autonomous: The most effective deployments augment people rather than replace them. Assistive agents are driving real ROI. Multilingual as standard: Real-time code-switching is now a baseline requirement, not a bonus. Accuracy is make-or-break: With growing global concerns over AI hallucinations, precision is essential — especially in compliance-heavy environments. Voice as infrastructure: Quietly embedded tools are outperforming headline-grabbing features. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. It's being embedded into workflows that demand speed, accuracy, and trust — from noisy control rooms to multilingual contact centres. The report closes with future-looking predictions, outlining the rise of emotionally intelligent, adaptive, and natively multilingual voice systems — and offers guidance on what enterprises must prioritise next.
Business Wire
2 hours ago
- Business Wire
FIA President Mohammed Ben Sulayem Looking Forward to Visiting ‘Iconic' Macau for the 2025 FIA Annual Conference
MACAU--(BUSINESS WIRE)--The Fédération Internationale de l'Automobile (FIA), the global governing body for motorsport and the federation for mobility organisations worldwide, will shortly be in Macau for the 2025 FIA Extraordinary General Assembly and Annual Conference. Marking the first time this event has ever taken place in this diverse region, the conference will be hosted in partnership with the Automobile General Association Macao-China (AAMC) and Galaxy Entertainment Group and held at the Galaxy International Convention Centre. The event will welcome over 500 senior FIA delegates across mobility and motorsport from 149 countries, offering the opportunity to address key initiatives in road safety, sustainable mobility, regional sporting growth, and innovation in transport, with the FIA President Mohammed Ben Sulayem in attendance. Speaking ahead of his visit to Macau, FIA President Mohammed Ben Sulayem said: 'Global gatherings like this are vital to the health of our federation. Bringing our community together allows us an invaluable opportunity for engagement and participation, particularly within a pivotal election year. 'The Members of the FIA are at the heart of everything we do, and I am looking forward to being inspired by and connected to them over the next few days, strengthening the link between sport and mobility, expanding our reach, and continuing to impact the global stage. 'I am incredibly proud of the progress we have made together during my first term in office and look forward to continuing that partnership going forward. I am committed to the transformation of the FIA, so it can be an even more positive force for society. Globally, we remain committed to growing motorsport participation through grassroots initiatives and accessibility programmes such as the Affordable Cross Car and the Global Karting Plan. 'At the same time, we continue to empower all regions through our mobility capabilities, maintaining a central role in the automotive industry and leading the dialogue on the future of sustainable cities, safety, and transport.' Commenting on the location of this year's conference, Ben Sulayem said: 'Macau is iconic within the world of motorsport and a fitting location for the FIA to host one of the most important weeks of our calendar. I look forward to seeing much of what this unique destination has to offer.' The conference follows the FIA's recent announcement regarding the FIA's significant financial turnaround and strongest results in almost ten years. Reporting a profit of €4.7m, and an operating income of €182m for 2024, this puts the FIA back in the black following the inheritance of a €-24.0m deficit in 2021 from the previous administration. The conference will be attended by representatives from the 245 FIA Member Clubs. This structure forms the backbone of the federation's governance and operations, with each full Member Club holding voting rights across the FIA's elections and regulatory decisions. Clubs are grouped into two primary categories, with some serving in both roles: Mobility Clubs – provide mobility services and represent the interest of road users, with a focus on road safety, travel and tourism, consumer rights, and sustainable mobility National Sporting Authorities (ASNs) – govern and develop motorsport at a national level, are responsible for sporting events, issuing licenses, and engagement across regulations The Fédération Internationale de l'Automobile (FIA) is the governing body for world motor sport and the federation for mobility organisations globally. It is a non-profit organisation committed to driving innovation and championing safety, sustainability and equality across motor sport and mobility. Founded in 1904, with offices in Paris, London and Geneva, the FIA brings together 245 Member Organisations across five continents, representing millions of road users, motor sport professionals and volunteers. It develops and enforces regulations for motor sport, including seven FIA World Championships, to ensure worldwide competitions are safe and fair for all. The 2025 FIA Conference is hosted in association with Galaxy Entertainment Group and will be held at the International Convention Centre from 10-12 June. The Galaxy International Convention Centre is situated within the Galaxy Macau Integrated Resort which regularly plays host to world class sporting and conference events, and international exhibitions.
Business Wire
2 hours ago
- Business Wire
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for . Upcoming presentation at BIO 2025 follows successful Series B funding round and encouraging data from ongoing trials The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. 'We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders,' said Stefano Portolano, CEO at Azafaros. 'With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need.' About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
